Effects of cilnidipine and L-type calcium channel blockers on renal functions in hypertensive patients: a meta-analysis of the randomized trials

doi:10.5246/jcps.2015.11.095

Abstract

Abstract:

In the present study, we aimed to evaluate the effects of cilnidipine and L-type calcium channel blockers (L-type CCBs) on renal function in hypertensive patients. The randomized controlled trials (RCTs) of cilnidipine and L-type CCBs on hypertension treatment were selected from Pubmed, Embase, Google Scholar, CNKI, Science Direct, Ebsco, Springer, Ovid, Cochrane Library, Medline, VIP and Wanfang databases (from the date of databases’ establishment to September 2014). Data were independently evaluated following the Jadad standard. The percentage changes of serum creatinine (SCr) value, urinary protein excretion (UPE), urinary protein/creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR) pre- and post-treatment were extracted for the subsequent meta-analysis. The mean difference (MD) and the 95% confidence interval (95% CI) were determined using RevMan 5.3 software.A total of 10 RCTs of high quality were included and analyzed by fixed- or random-effect models. The results indicated that UPE (MD = –36.59, 95% CI: –70.85, –2.33) or UPCR (MD = –46.56, 95% CI: –88.50, –4.62) was significantly reduced by cilnidipine compared with L-type CCBs. However, such significant difference was not detected in reduction of SCr (MD = 0.01, 95% CI: –2.97, 2.98) or eGFR (MD = 1.56, 95% CI: –0.19, 3.31). Compared with L-type CCBs, cilnidipine was more effective in reducing proteinuria or preventing the proteinuria progression. In addition, we did not find significant differences in SCr and eGFR between the two groups.

Key words: Cilnidipine, L-type CCBs, Renal function, Meta-analysis, Randomized controlled trial

CLC Number:

R962.1

Supporting:

Xiaochun Ye, Zhi Dong, Chunjing Zhao, Di Li, Yan Qian. Effects of cilnidipine and L-type calcium channel blockers on renal functions in hypertensive patients: a meta-analysis of the randomized trials[J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(11): 744-753.

References

[1] Fu, Q.; Levine, B.D. Hypertension. 2006, 3, 323-324.
[2] Ewen, S.; Ukena, C.; Linz, D.; Schmieder, R.E.; Bohm, M.; Mahfoud, F. Curr. Hypertens Rep. 2013, 15, 370-376.

[3] Hausberg, M.; Kosch, M.; Harmelink, P.; Barenbrock, M.; Hohage, H.; Kisters, K.; Dietl, K.H.; Rahn, K.H. Circulation.2002, 106, 1974-1979.

[4] James, P.A. 2014, 311, 507-520. This article can be found online at http://jama.jamanetwork.com/on 02/02/2014/JAMA. doi:10.1001/jama.2013.284427JAMA.

[5] Uneyama, H.; Takahara, A.; Dohmoto, H.; Yoshimoto, R.; Inoue, K.; Akaike, N. Brit. J. Pharmacol. 1997, 122, 37-42.

[6] Hirning, L.D.; Fox, A.P.; McCleskey, E.W.; Oliver, B.M.; Thayer, S.A.; Miller, R.J.; Tsien, R.W. Science. 1988, 239, 57-61.

[7] Murakami, M.; Ohba, T.; Xu, F.; Sstoh, E.; Miyoshi, L.; Suzuki, T.; Takahashi, Y.; Takahashi, E.; Watanaba, H.; Ono, K.; Sasano, H.; Kasai, N.; lto, H.; lijima, T. J. Biol. Chem. 2008, 283, 24554-24560.

[8] Fujii, S.; Kameyama, K.; Hosono, M.; Hayashi, Y.; Kitamura, K. Pharmacol. Exp. Ther. 1997, 280, 1184-1191.

[9] Salomonsson, M.; Brannstrom, K.; Arendshorst, W.J. Am. J. Physiol-Renal. Physiol. 2000, 278, F138-F147.

[10] Alexander, N.; Marie, J.M.; Jippe, C.B.; Martin, P.; Pieter, A.V.Z. Fundam. Clin. Pharmacol. 2004, 18, 309-319.

[11] Malleshappa, P. Dial. Traspl. 2013, 34, 2-6.

[12] Jadad, A.R.; Moore, R.A.; Carroll, D.; Jenkinson, C.; Reynolds, D.J.; Gavaqhan, D.J.; McQuay, H.J. Control. Clin. Trials. 1996, 17, 1-12.

[13] Higgins, J.P. Deeks, J.J. Altman, D.G. editors. Chapter 16: special topics in statistics. In Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.3. The Cochrane Collaboration, 2014. Available from www.cochrane-handbook.org

[14] Follmann, D.; Elliott, P.; Suh, I.; Cutler, J. Clin. Epidemiol. 1992, 45, 769-773.

[15] Takagi, H.; Yamamoto, H.; Iwata, K.; Goto, S.N.; Umemoto, T. Int. J. Cardiol. 2013, 167, 1443-1449.

[16] Ando, K.; Ueshima, K.; Tanaka, S.; Kosuqi, S.; Sato, T.; Matsuoka, H.; Nakao, K.; Fujita, T. Int. J. Med. Sci. 2013, 10, 1209-1216.

[17] Abe, M.; Maruyama, N.; Suzuki, H.; lnoshita, A.; Yoshida, Y.; Okada, K.; Soma, M. Heart Vessels. 2013, 28, 480-489.

[18] Kojima, S., Shida, M., Yokoyama, H. Hypertens Res. 2004, 27, 379-385.

[19] Fujita, T.; Ando, K.; Nishimura, H.; ldeura T.; Yasuda, G.; lsshiki, M.; Takahashi, K. Kidney Int. 2007, 72, 1543-1549.

[20] Konoshita, T.; Makino, Y.; Kimura, T.; Fujii, M.; Wakahara, S.; Arakawa, K.; lnoki, l.; Nakamura, H.; Miyamori, I. J. Hypertens. 2010, 28, 2156-2160.

[21] Kanaoka, T.; Tamura, K.; Wakui, H.; Ohsawa, M.; Azushima, K.; Uneda, K.; Kobayashi, R.; Fujikawa, T.; Tsurumi-Ikeya, Y.; Maeda, A.; Yanaqi, M.; Toya, Y.; Umemura, S. Int. J. Mol. Sci. 2013, 14, 16866-16881.

[22] Satomura, A.; Fujita, T.; Fuke, Y.; Wada, Y.; Matsumoto, K. Open Clin. Chem. J. 2009, 2, 31-36.

[23] Miwa, Y.; Tsuchihash, T.; Ohta, Y.;Tominaga M.; Kawano, Y.; Sasaguri, T.; Ueno, M.; Matsuoka, H. Clin. Exp. Hypertens.2010, 32, 400-405.

[24] Cao, B.Q.; Liu, D.Y.; Wang, S.Z.; Fan, Y.G. China Med. 2010, 5, 494-496.

[25] Morimoto, S.; Yanoa, Y.; Maki, K.; Iwasaka, T.J. Hypertens. 2007, 25, 2178-2183.

[26] Iseki, K.; Ikemiya, Y.; Iseki, C.; Takishita, S. Kidney Int. 2003, 63, 1468-1474.

[27] Brenner, B.M.; Cooper, M.E.; de Zeeuw, D.; Keane, W.F.; Mitch, W.E.; Parving, H.H.; Remuzzi, G.; Snapinn, S.M.; Zhang, Z.; Shahinfar, S. N. Engl. J. Med. 2001, 345, 861-869.
[28] Peterson, J.C.; Adler, S.; Burkart, J.M.; Greene, T.; Hebert, L.A.; Hunsicker, L.G.; King, A.J.; Klahr, S Massry, S.G.; Seifter, J.L. Ann. Intern. Med. 1995, 123, 754-762.